Author

Hannah Elizabeth Dzimitrowicz

Observed names: Hannah Dzimitrowicz, Hannah E. Dzimitrowicz

Observed institutions: Yale New Haven Hospital, The University of Texas MD Anderson Cancer Center, Duke University, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Yale University, Duke Medical Center, Smilow Cancer Hospital, Duke Cancer Institute, The Ohio State University, University of Cincinnati, University of Cincinnati Medical Center

OpenAlex ID: A5033486347

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study

2019 · Nieves Martínez Chanzá, Wanling Xie, et al. · The Lancet Oncology · 174

Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma

2021 · Laure Hirsch, Nieves Martinez Chanza, et al. · JAMA Oncology · 84

PDF

T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab

2016 · Hannah Dzimitrowicz, Michael Berger, et al. · Journal of Clinical Oncology · 80

A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice

2014 · Neil Vasan, Roman Yelensky, et al. · The Oncologist · 62

PDF

Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19

2022 · Ziad Bakouny, Chris Labaki, et al. · JAMA Oncology · 54

PDF

Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19

2021 · Andrew L. Schmidt, Matthew D. Tucker, et al. · JAMA Network Open · 38

PDF

Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study

2020 · Nieves Martinez Chanza, Wanling Xie, et al. · Journal for ImmunoTherapy of Cancer · 34

PDF

Bridging New Technology Into Clinical Practice With Mobile Apps, Electronic Patient-Reported Outcomes, and Wearables

2022 · Hannah E. Dzimitrowicz, L. Johnetta Blakely, et al. · American Society of Clinical Oncology Educational Book · 21

PDF

Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy

2023 · Justine Panian, Ava Saidian, et al. · The Oncologist · 20

PDF

Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19

2023 · Shuchi Gulati, Chih-Yuan Hsu, et al. · JAMA Oncology · 10

PDF

Triplet Therapy: Entering the Metaverse of Metastatic Hormone-sensitive Prostate Cancer Treatment

2022 · Hannah E. Dzimitrowicz, Andrew J. Armstrong · European Urology · 9

Activity and safety of cabozantinib (cabo) in brain metastases (BM) from metastatic renal cell carcinoma (mRCC): An international multicenter study.

2021 · Laure Hirsch, Nieves Martinez Chanza, et al. · Journal of Clinical Oncology · 7

Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making

2017 · Hannah Dzimitrowicz, Sarah Mougalian, et al. · Journal of Oncology Practice · 7

Pathologic outcomes at cytoreductive nephrectomy (CN) following immunotherapy (IO) for patients with advanced renal cell carcinoma (RCC).

2022 · Justine Panian, Ava Saidian, et al. · Journal of Clinical Oncology · 3

Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma

2023 · Douglas B. Johnson, Michael B. Atkins, et al. · BMC Cancer · 2

PDF

Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC).

2021 · Tyler F. Stewart, Nikhil V. Kotha, et al. · Journal of Clinical Oncology · 2

Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC).

2021 · Akram Mesleh Shayeb, Danielle Urman, et al. · Journal of Clinical Oncology · 2

Impact of neoadjuvant immune checkpoint inhibitor therapy on primary tumor size and complexity: Correlation with surgical quality and short term oncological outcomes.

2022 · Ava Saidian, Kevin Hakimi, et al. · Journal of Clinical Oncology · 1

Provider referral patterns following nephrectomy in high-risk locoregional renal cell carcinoma.

2020 · Hannah Elizabeth Dzimitrowicz, Elizabeth Esterberg, et al. · Journal of Clinical Oncology · 1

Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC).

2019 · Nieves Martinez Chanza, Wanling Xie, et al. · Journal of Clinical Oncology · 1

COVID-19 in Patients With Gynecologic Cancer: A Report From the COVID-19 and Cancer Consortium

2026 · Alaina J. Brown, Chih-Yuan Hsu, et al. · JCO oncology advances.

Pd24-04 Outcomes of Deferred Cytoreductive Nephrectomy Following Primary Immunotherapy in Advanced Renal Cell Carcinoma: a Multicenter Analysis

2023 · Kevin Hakimi, Ava Saidian, et al. · The Journal of Urology

Body composition in patients with metastatic renal cell carcinoma receiving ipilimumab plus nivolumab.

2022 · Hannah Elizabeth Dzimitrowicz, Fides Schwartz, et al. · Journal of Clinical Oncology

Moving Beyond BMI – Developments in Body Composition and Muscle Measurement in Renal Cell Carcinoma

2022 · Hannah Dzimitrowicz, Jordan Infield, et al. · Kidney Cancer Journal

Factors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma.

2022 · Hannah Elizabeth Dzimitrowicz, Lauren E. Wilson, et al. · Journal of Clinical Oncology

Works count: 28

Citation count: 612

H-index: 10

I10-index: 10